Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 8/20 | 0.63 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480702 | 1.00 | PRKCA (0.63) | PRKCAPRKCEPRKCQPRKCDBLM | |
| SCHEMBL9452155 | 1.00 | PRKCA (0.63) | PRKCAPRKCEPRKCQPRKCDBLM | |
| SCHEMBL30557897 | 0.91 | PRKCA (0.47) | PRKCAPRKCEPRKCQPRKCDBLM | |
| SCHEMBL21686371 | 0.90 | PRKCA (0.50) | PRKCAPRKCEPRKCQPRKCDBLM | |
| SCHEMBL234142 | 0.82 | ENPP2 (0.51) | PRKCA | |
| SCHEMBL23706432 | 0.82 | LMNA (0.46) | PRKCABLM | |
| SCHEMBL1521671 | 0.81 | PRKCA (0.42) | PRKCABLM | |
| SCHEMBL26236288 | 0.81 | SELP (0.49) | PRKCA | |
| SCHEMBL14415223 | 0.81 | PRKCA (0.74) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL3574597 | 0.81 | BLM (0.41) | PRKCABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054991-A1 | PORIN-MEMBRANE FUSION METHOD, PORIN INSERTION BUFFER SOLUTION, AND USE | 深圳华大生命科学研究院 | 2025-03-20 | — | — | WO | claimed |
| WO-2025002352-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF | 上海瑞宏迪医药有限公司 | 2025-01-02 | — | — | WO | claimed |
| WO-2024098361-A1 | ARTIFICIAL NUCLEIC ACID MOLECULE | 斯微(上海)生物科技股份有限公司 | 2024-05-16 | — | — | WO | claimed |
| WO-2024098360-A1 | ARTIFICIAL NUCLEIC ACID MOLECULE | 斯微(上海)生物科技股份有限公司 | 2024-05-16 | — | — | WO | claimed |
| CN-115968280-A | Novel lipids and nanoparticle compositions thereof | 世代生物公司 | 2023-04-14 | — | — | CN | claimed |
| US-12559774-B2 | CRISPR enzymes and systems | THE BROAD INSTITUTE, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250327810-A1 | SEQUENCE-DETECTION SYSTEM | ILLUMINA INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12292446-B2 | Kits for analysis using nucleic acid encoding and/or label | Encodia, Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250102513-A1 | KITS FOR ANALYSIS USING NUCLEIC ACID ENCODING AND/OR LABEL | Encodia, Inc. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2025054991-A1 | PORIN-MEMBRANE FUSION METHOD, PORIN INSERTION BUFFER SOLUTION, AND USE | 深圳华大生命科学研究院 | 2025-03-20 | — | — | WO | disclosed |
| US-20250060371-A1 | KITS FOR ANALYSIS USING NUCLEIC ACID ENCODING AND/OR LABEL | Encodia, Inc. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240377409-A1 | KITS FOR ANALYSIS USING NUCLEIC ACID ENCODING AND/OR LABEL | DF PEPTIDE ACQUISITION LLC | 2024-11-14 | — | — | US | disclosed |
| US-20220164126-A1 | ANALYTE SEQUENCING WITH NANOPORES | UNIVERSITY OF WASHINGTON (US) | 2022-05-26 | — | — | US | disclosed |
| CN-111225744-B | Protein nanopores removal and reinsertion into membranes using osmotic imbalance | 豪夫迈·罗氏有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-113767280-A | Systems and methods for inserting nanopores in membranes using osmotic imbalance | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-113260449-A | Systems and methods for self-limiting protein pore insertion in membranes | 豪夫迈·罗氏有限公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-112292462-A | Multiplexing analog components in a biochemical sensor array | 豪夫迈·罗氏有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-111225744-A | Protein nanopores removal and reinsertion into membranes using osmotic imbalance | 豪夫迈·罗氏有限公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2012102584-A9 | SENSOR FOR DETECTING TARGET VIRUS, AND METHOD FOR SCREENING TARGET VIRUS AND ANALYZING MUTATION LOCATION USING SAME | 서울대학교 산학협력단 (KR) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012102584-A2 | SENSOR FOR DETECTING TARGET VIRUS, AND METHOD FOR SCREENING TARGET VIRUS AND ANALYZING MUTATION LOCATION USING SAME | 서울대학교 산학협력단 (KR) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559774-B2 | CRISPR enzymes and systems | CPSF1, CPSF6, FEN1 | PRKCA 1998/4885PRKCE 1567/4885PRKCQ 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.